Nucleic acids involved in viral infection

Abstract

Provided herein are isolated viral and human nucleic acids associated with viral infection and various nucleic acid molecules relating thereto or derived therefrom. The nucleic acids may be useful for the prevention, treatment and diagnosis of viral infections.

1 .- 6 . (canceled) 
     
     
         7 . A method of preventing or treating viral infection or a condition associated with a viral infection in a subject in need thereof comprising administering to the subject an effective amount of a composition comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 1-9,221, 15,366-15,392 and 15,516-15,527; a complementary sequence thereof; and a sequence at least about 80% identical thereto. 
     
     
         8 . The method of  claim 7 , wherein the viral infection is selected from the group consisting of HSV1, HSV2, RSV, EBV, Influenza A, HCV, HPV, HIV, HBV and Vaccinia virus infection. 
     
     
         9 . A method of inhibiting expression of a target gene in a cell comprising introducing a nucleic acid into the cell in an amount sufficient to inhibit expression of the target gene, wherein the target gene comprises a binding site substantially identical to a binding site as set forth in any one of SEQ ID NOS: 9,222-15,365, 15,393-15,515; and wherein the nucleic acid is a nucleic acid selected from the group consisting of SEQ ID NOS: 1-9,221, 15,366-15,392, and 15,516-15,527; a complementary sequence thereof; and a sequence at least about 80% identical thereto. 
     
     
         10 .- 18 . (canceled) 
     
     
         19 . A method of reducing the amount of virus replication in a target cell, said method comprising: introducing into a target cell infected with the virus an effective amount of a composition comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 1-9,221, 15,366-15,392 and 15,516-15,527; a complementary sequence thereof; and a sequence at least about 80% identical thereto. 
     
     
         20 . The method of  claim 19 , wherein said target cell is in vitro. 
     
     
         21 . The method of  claim 19 , wherein said target cell is in vivo. 
     
     
         22 . The method of  claim 21 , wherein said method comprises administering the composition to a subject comprising said target cell. 
     
     
         23 . The method of  claim 19 , wherein said virus is selected from the group consisting of HSV1, HSV2, RSV, EBV, Influenza A, HCV, HPV, HIV, HBV and Vaccinia. 
     
     
         24 . The method of  claim 19 , wherein said method comprises treating said subject for viral mediated disease condition. 
     
     
         25 . The method of  claim 24 , wherein said disease condition is selected from the group consisting of Burkitt's lymphoma, nasopharingal carcinoma, ovarian carcinoma, cervical cancer, hepatitis, mononucleosis, influenza, genital herpes, encephalitis, and bronchiolitis.